

Global Cell-Free Circulating Tumor DNA (ctDNA) Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/GCA94818236EEN.html>

Date: May 2026

Pages: 123

Price: US\$ 3,660.00 (Single User License)

ID: GCA94818236EEN

Abstracts

The global Cell-Free Circulating Tumor DNA (ctDNA) market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Cell-free circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies.

United States market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Cell-Free Circulating Tumor DNA (ctDNA) is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Cell-Free Circulating Tumor DNA (ctDNA) players cover Nexomics, Roche, ORIOMICS, Signatera, Illumina, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the "Cell-Free Circulating Tumor DNA (ctDNA) Industry Forecast" looks at past sales and reviews total world Cell-Free Circulating Tumor DNA (ctDNA) sales in 2025, providing a comprehensive analysis by

region and market sector of projected Cell-Free Circulating Tumor DNA (ctDNA) sales for 2026 through 2032. With Cell-Free Circulating Tumor DNA (ctDNA) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Cell-Free Circulating Tumor DNA (ctDNA) industry.

This Insight Report provides a comprehensive analysis of the global Cell-Free Circulating Tumor DNA (ctDNA) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell-Free Circulating Tumor DNA (ctDNA) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cell-Free Circulating Tumor DNA (ctDNA) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell-Free Circulating Tumor DNA (ctDNA) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell-Free Circulating Tumor DNA (ctDNA).

This report presents a comprehensive overview, market shares, and growth opportunities of Cell-Free Circulating Tumor DNA (ctDNA) market by product type, application, key players and key regions and countries.

Segmentation by Type:

Gastric Cancer Methylation Screening

Esophageal Cancer Methylation Screening

Colorectal Cancer Methylation Screening

Lung Cancer Methylation Screening

Liver Cancer Methylation Screening

Other Cancer Screening

Segmentation by Application:

Hospital

Medical Center

Laboratory

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Nexomics

Roche

ORIOMICS

Signatera

Illumina

Sysmex Corporation

Bio-Rad

Biocartis

QIAGEN

GuardantHealth

GSK plc

AstraZeneca

NeoGenomics Laboratories

AmoyDx

Annoroad

Burning Rock Biotech

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (2021-2032)
- 2.1.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Region (2021 VS 2025 VS 2032)
- 2.1.3 World Current & Future Analysis for Cell-Free Circulating Tumor DNA (ctDNA) by Country/Region (2021, 2025 & 2032)

2.2 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type

- 2.2.1 Gastric Cancer Methylation Screening
- 2.2.2 Esophageal Cancer Methylation Screening
- 2.2.3 Colorectal Cancer Methylation Screening
- 2.2.4 Lung Cancer Methylation Screening
- 2.2.5 Liver Cancer Methylation Screening
- 2.2.6 Other Cancer Screening
- 2.2.7 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
 - 2.2.7.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.7.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)

2.3 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application

- 2.3.1 Hospital
- 2.3.2 Medical Center
- 2.3.3 Laboratory
- 2.3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
 - 2.3.4.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Application

(2021 VS 2025 VS 2032)

2.3.4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)

3 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SIZE BY PLAYER

3.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Player

3.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Player (2021-2026)

3.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player (2021-2026)

3.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) BY REGION

4.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026)

4.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Annual Revenue by Country/Region (2021-2026)

4.3 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)

4.4 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)

4.5 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)

4.6 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026)

5.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)

5.3 Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
(2021-2026)

6.2 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)

6.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
(2021-2026)

7.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026)

7.3 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) by Region
(2021-2026)

8.2 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type
(2021-2026)

8.3 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by

Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET FORECAST

10.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)

10.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)

10.1.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.1.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.1.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.1.5 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.2 Americas Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Country (2027-2032)

10.2.1 United States Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.2.2 Canada Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.2.3 Mexico Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.2.4 Brazil Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.3 APAC Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)

10.3.1 China Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast

10.3.2 Japan Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.3.3 Korea Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.3.4 Southeast Asia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.3.5 India Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.3.6 Australia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

10.4 Europe Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Country (2027-2032)

10.4.1 Germany Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

- 10.4.2 France Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
- 10.4.3 UK Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
- 10.4.4 Italy Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
- 10.4.5 Russia Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
- 10.5 Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
 - 10.5.2 South Africa Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
 - 10.5.3 Israel Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
 - 10.5.4 Turkey Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast
- 10.6 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Type (2027-2032)
- 10.7 Global Cell-Free Circulating Tumor DNA (ctDNA) Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Cell-Free Circulating Tumor DNA (ctDNA) Forecast

11 KEY PLAYERS ANALYSIS

11.1 Nexomics

- 11.1.1 Nexomics Company Information
- 11.1.2 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
- 11.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
- 11.1.4 Nexomics Main Business Overview
- 11.1.5 Nexomics Latest Developments

11.2 Roche

- 11.2.1 Roche Company Information
- 11.2.2 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
- 11.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
- 11.2.4 Roche Main Business Overview
- 11.2.5 Roche Latest Developments

11.3 ORIOMICS

- 11.3.1 ORIOMICS Company Information
- 11.3.2 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
- 11.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
- 11.3.4 ORIOMICS Main Business Overview
- 11.3.5 ORIOMICS Latest Developments

11.4 Signatera

- 11.4.1 Signatera Company Information
- 11.4.2 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
- 11.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
- 11.4.4 Signatera Main Business Overview
- 11.4.5 Signatera Latest Developments
- 11.5 Illumina
 - 11.5.1 Illumina Company Information
 - 11.5.2 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.5.4 Illumina Main Business Overview
 - 11.5.5 Illumina Latest Developments
- 11.6 Sysmex Corporation
 - 11.6.1 Sysmex Corporation Company Information
 - 11.6.2 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Sysmex Corporation Main Business Overview
 - 11.6.5 Sysmex Corporation Latest Developments
- 11.7 Bio-Rad
 - 11.7.1 Bio-Rad Company Information
 - 11.7.2 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 Bio-Rad Main Business Overview
 - 11.7.5 Bio-Rad Latest Developments
- 11.8 Biocartis
 - 11.8.1 Biocartis Company Information
 - 11.8.2 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 Biocartis Main Business Overview
 - 11.8.5 Biocartis Latest Developments
- 11.9 QIAGEN
 - 11.9.1 QIAGEN Company Information
 - 11.9.2 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)

- 11.9.4 QIAGEN Main Business Overview
- 11.9.5 QIAGEN Latest Developments
- 11.10 GuardantHealth
 - 11.10.1 GuardantHealth Company Information
 - 11.10.2 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.10.4 GuardantHealth Main Business Overview
 - 11.10.5 GuardantHealth Latest Developments
- 11.11 GSK plc
 - 11.11.1 GSK plc Company Information
 - 11.11.2 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 GSK plc Main Business Overview
 - 11.11.5 GSK plc Latest Developments
- 11.12 AstraZeneca
 - 11.12.1 AstraZeneca Company Information
 - 11.12.2 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.12.4 AstraZeneca Main Business Overview
 - 11.12.5 AstraZeneca Latest Developments
- 11.13 NeoGenomics Laboratories
 - 11.13.1 NeoGenomics Laboratories Company Information
 - 11.13.2 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 NeoGenomics Laboratories Main Business Overview
 - 11.13.5 NeoGenomics Laboratories Latest Developments
- 11.14 AmoyDx
 - 11.14.1 AmoyDx Company Information
 - 11.14.2 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.14.4 AmoyDx Main Business Overview
 - 11.14.5 AmoyDx Latest Developments
- 11.15 Annoroad

- 11.15.1 Annoroad Company Information
- 11.15.2 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
- 11.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
- 11.15.4 Annoroad Main Business Overview
- 11.15.5 Annoroad Latest Developments
- 11.16 Burning Rock Biotech
 - 11.16.1 Burning Rock Biotech Company Information
 - 11.16.2 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Offered
 - 11.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue, Gross Margin and Market Share (2021-2026)
 - 11.16.4 Burning Rock Biotech Main Business Overview
 - 11.16.5 Burning Rock Biotech Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Cell-Free Circulating Tumor DNA (ctDNA) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Gastric Cancer Methylation Screening

Table 4. Major Players of Esophageal Cancer Methylation Screening

Table 5. Major Players of Colorectal Cancer Methylation Screening

Table 6. Major Players of Lung Cancer Methylation Screening

Table 7. Major Players of Liver Cancer Methylation Screening

Table 8. Major Players of Other Cancer Screening

Table 9. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (\$ millions)

Table 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)

Table 12. Cell-Free Circulating Tumor DNA (ctDNA) Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (\$ millions)

Table 14. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)

Table 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Player (2021-2026) & (\$ millions)

Table 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player (2021-2026)

Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Key Players Head office and Products Offered

Table 18. Cell-Free Circulating Tumor DNA (ctDNA) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 19. New Products and Potential Entrants

Table 20. Mergers & Acquisitions, Expansion

Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & (\$ millions)

Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share

by Region (2021-2026)

Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue by Country/Region (2021-2026) & (\$ millions)

Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Country/Region (2021-2026)

Table 25. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & (\$ millions)

Table 26. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country (2021-2026)

Table 27. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (\$ millions)

Table 28. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)

Table 29. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (\$ millions)

Table 30. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)

Table 31. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & (\$ millions)

Table 32. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)

Table 33. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (\$ millions)

Table 34. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (\$ millions)

Table 35. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2021-2026) & (\$ millions)

Table 36. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country (2021-2026)

Table 37. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (\$ millions)

Table 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (\$ millions)

Table 39. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2021-2026) & (\$ millions)

Table 40. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (2021-2026) & (\$ millions)

Table 41. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2021-2026) & (\$ millions)

Table 42. Key Market Drivers & Growth Opportunities of Cell-Free Circulating Tumor DNA (ctDNA)

Table 43. Key Market Challenges & Risks of Cell-Free Circulating Tumor DNA (ctDNA)

Table 44. Key Industry Trends of Cell-Free Circulating Tumor DNA (ctDNA)

Table 45. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 46. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Region (2027-2032)

Table 47. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 48. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 49. Nexomics Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 50. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 51. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 52. Nexomics Main Business

Table 53. Nexomics Latest Developments

Table 54. Roche Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 55. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 56. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 57. Roche Main Business

Table 58. Roche Latest Developments

Table 59. ORIOMICS Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 60. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 61. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 62. ORIOMICS Main Business

Table 63. ORIOMICS Latest Developments

Table 64. Signatera Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 65. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 66. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 67. Signatera Main Business

Table 68. Signatera Latest Developments

Table 69. Illumina Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 70. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 71. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 72. Illumina Main Business

Table 73. Illumina Latest Developments

Table 74. Sysmex Corporation Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 75. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 76. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 77. Sysmex Corporation Main Business

Table 78. Sysmex Corporation Latest Developments

Table 79. Bio-Rad Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 80. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 81. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 82. Bio-Rad Main Business

Table 83. Bio-Rad Latest Developments

Table 84. Biocartis Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 85. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 86. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 87. Biocartis Main Business

Table 88. Biocartis Latest Developments

Table 89. QIAGEN Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 90. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 91. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 92. QIAGEN Main Business

Table 93. QIAGEN Latest Developments

Table 94. GuardantHealth Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 95. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 96. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 97. GuardantHealth Main Business

Table 98. GuardantHealth Latest Developments

Table 99. GSK plc Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 100. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 101. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 102. GSK plc Main Business

Table 103. GSK plc Latest Developments

Table 104. AstraZeneca Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 105. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 106. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 107. AstraZeneca Main Business

Table 108. AstraZeneca Latest Developments

Table 109. NeoGenomics Laboratories Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 110. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 111. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 112. NeoGenomics Laboratories Main Business

Table 113. NeoGenomics Laboratories Latest Developments

Table 114. AmoyDx Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 115. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 116. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 117. AmoyDx Main Business

Table 118. AmoyDx Latest Developments

Table 119. Annoroad Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 120. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 121. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 122. Annoroad Main Business

Table 123. Annoroad Latest Developments

Table 124. Burning Rock Biotech Details, Company Type, Cell-Free Circulating Tumor DNA (ctDNA) Area Served and Its Competitors

Table 125. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Offered

Table 126. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 127. Burning Rock Biotech Main Business

Table 128. Burning Rock Biotech Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Cell-Free Circulating Tumor DNA (ctDNA) Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Cell-Free Circulating Tumor DNA (ctDNA) Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Cell-Free Circulating Tumor DNA (ctDNA) Sales Market Share by Country/Region (2025)

Figure 8. Cell-Free Circulating Tumor DNA (ctDNA) Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type in 2025

Figure 10. Cell-Free Circulating Tumor DNA (ctDNA) in Hospital

Figure 11. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Hospital (2021-2026) & (\$ millions)

Figure 12. Cell-Free Circulating Tumor DNA (ctDNA) in Medical Center

Figure 13. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Medical Center (2021-2026) & (\$ millions)

Figure 14. Cell-Free Circulating Tumor DNA (ctDNA) in Laboratory

Figure 15. Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Laboratory (2021-2026) & (\$ millions)

Figure 16. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application in 2025

Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Player in 2025

Figure 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2021-2026)

Figure 19. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 (\$ millions)

Figure 20. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 (\$ millions)

Figure 21. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 (\$ millions)

Figure 22. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2021-2026 (\$ millions)

Figure 23. Americas Cell-Free Circulating Tumor DNA (ctDNA) Value Market Share by Country in 2025

Figure 24. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 25. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 26. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 27. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 28. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region in 2025

Figure 29. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)

Figure 30. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)

Figure 31. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 32. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 33. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 34. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 35. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 36. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 37. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2025

Figure 38. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2021-2026)

Figure 39. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Application (2021-2026)

Figure 40. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth 2021-2026 (\$ millions)

Figure 41. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth

2021-2026 (\$ millions)

Figure 42. UK Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth

2021-2026 (\$ millions)

Figure 43. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth

2021-2026 (\$ millions)

Figure 44. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth

2021-2026 (\$ millions)

Figure 45. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size
Market Share by Region (2021-2026)

Figure 46. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size
Market Share by Type (2021-2026)

Figure 47. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size
Market Share by Application (2021-2026)

Figure 48. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth

2021-2026 (\$ millions)

Figure 49. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth

2021-2026 (\$ millions)

Figure 50. Israel Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth

2021-2026 (\$ millions)

Figure 51. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth

2021-2026 (\$ millions)

Figure 52. GCC Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size
Growth 2021-2026 (\$ millions)

Figure 53. Americas Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032
(\$ millions)

Figure 54. APAC Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$
millions)

Figure 55. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$
millions)

Figure 56. Middle East & Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size
2027-2032 (\$ millions)

Figure 57. United States Cell-Free Circulating Tumor DNA (ctDNA) Market Size
2027-2032 (\$ millions)

Figure 58. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$
millions)

Figure 59. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$
millions)

Figure 60. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$
millions)

Figure 61. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 62. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 63. Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 64. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 65. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 66. Australia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 67. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 68. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 69. UK Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 70. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 71. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 72. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 73. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 74. Israel Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 75. Turkey Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

Figure 76. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Type (2027-2032)

Figure 77. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share Forecast by Application (2027-2032)

Figure 78. GCC Countries Cell-Free Circulating Tumor DNA (ctDNA) Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Cell-Free Circulating Tumor DNA (ctDNA) Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/GCA94818236EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCA94818236EEN.html>